Treatment options after first-line immunotherapy in metastatic NSCLC.

Santos, Edgardo S

Santos, Edgardo S.

Affiliation

Santos ES; Florida Precision Oncology, a Division of 21st Century Oncology, Aventura, Florida.

Expert Rev Anticancer Ther ; 20(3): 221-228, 2020 03.

Article in En | MEDLINE | ID: mdl-32141356

Subject(s)

Carcinoma, Non-Small-Cell Lung/therapy; Immunotherapy/methods; Lung Neoplasms/therapy; Carcinoma, Non-Small-Cell Lung/immunology; Carcinoma, Non-Small-Cell Lung/pathology; Humans; Immune Checkpoint Inhibitors/administration & dosage; Immune Checkpoint Inhibitors/adverse effects; Immunotherapy/adverse effects; Lung Neoplasms/immunology; Lung Neoplasms/pathology; Quality of Life; Survival Rate

Key words

Checkpoint inhibition; immunotherapy resistance; mechanism of resistance; non-small cell lung cancer; second line

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Immunotherapy / Lung Neoplasms Language: En Journal: Expert Rev Anticancer Ther Year: 2020 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google